Fig. 5: Variant RBD-NP vaccines elicit high neutralizing Ab titers to SARS-CoV-2 variants in mice. | npj Vaccines

Fig. 5: Variant RBD-NP vaccines elicit high neutralizing Ab titers to SARS-CoV-2 variants in mice.

From: Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens

Fig. 5

A, C Immunization scheme of VOC-RBD-NP, VOC-HexaPro, and the NP scaffold (Bare-NP) vaccines in Balb/c mice. Structural models of VOC-RBD-NPs, VOC-HexaPro, and Bare-NP vaccines. B, D Two weeks post boost neutralizing Ab titers for monovalent (RBD-NP), mosaics (m), and cocktails (c) of VOC with and without Rpk9 (+/−) mutations, Bare-NP, WT-VOC-HexaPro, and cocktails (c) of WT-VOC-HexaPro against various VOC pseudoviruses. Background neutralization is denoted by a dotted line. E Immunization scheme of VOC-RBD-NP vaccines in Darwin mice. Structural models of VOC-RBD-NP vaccines. F 0.5 week post IV boost neutralizing Ab titers for VOC-RBD-NP vaccines against various VOC pseudoviruses. Cocktail formulations including Wu-1-RBD-NP were formulated with βRpk9-RBD-NP or γRpk9-RBD-NP. All graphical representations of proteins made using ChimeraX61. Detailed RBD-NP immunogen information can be found in Supplementary Table 2. Kruskal–Wallis tests were performed to compare two groups to determine whether they were statistically different. Significance is indicated with stars: ∗p < 0.05; ∗∗p < 0.01; and non-significant differences are not shown.

Back to article page